Overview Experience Events News Intelligence Courtenay C. Brinckerhoff Partner cbrinckerhoff foley.com Download vCard 12345next In Uship Federal Circuit Finds Prosecution History Disclaimer in Arguments Against Restriction Requirement 23 May 2013 PharmaPatents In Uship Intellectual Properties, LLC v. United States, the Federal Circuit upheld the claim construction applied by the Court of Federal Claims when it held that... USPTO Launches New After Final Consideration Pilot Program to Reduce Requests for Continued Examination (RCEs) 20 May 2013 PharmaPatents In a Federal Register Notice published on May 17, 2013, the USPTO announced After Final Consideration Pilot Program 2.0 (AFCP 2.0) as part of its ongoing efforts... Supreme Court Finds for Monsanto in Seed Harvesting Case 16 May 2013 PharmaPatents In Bowman v. Monsanto Co., the Supreme Court held that the doctrine of patent exhaustion does not give a farmer who has bought patented seeds the right to “reproduce”... Federal Circuit Issues Fractured Affirmance in CLS Bank v. Alice Corporation 13 May 2013 PharmaPatents In a fractured en banc decision, the Federal Circuit affirmed the district court’s holding that the claims at issue in CLS Bank v. Alice Corporation are invalid... USPTO Reshuffles the RCE Deck 09 May 2013 PharmaPatents The USPTO still is considering information gathered during its RCE Outreach program, but it has made some internal changes that should lead to more prompt examination... Federal Circuit Upholds One Claim Covering Combigan 07 May 2013 PharmaPatents In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit reversed the district court in part, finding that Allergan’s composition claims and most of its method claims... Federal Circuit Holds That Patent Indefiniteness Requires Insoluble Ambiguousness 02 May 2013 PharmaPatents In Biosig Instruments, Inc. v. Nautilus Inc., the Federal Circuit reversed the district court’s finding that the claims at issue were invalid as indefinite, because... Dispelling the Myriad Gene Patent Harmonization Myth 30 April 2013 PharmaPatents In the wake of the Supreme Court oral arguments in the Myriad “gene patent” case, most commentators are predicting that the Court will uphold the patent-eligibility... Federal Circuit Finds Yaz Patent Obvious 25 April 2013 PharmaPatents In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer’s patent covering... Challenging the Enabling Quality of Prior Art 18 April 2013 PharmaPatents In In re Morsa, the Federal Circuit reversed an anticipation rejection where the applicant had challenged the enabling quality of the cited prior art reference,... 12345next Related 1 2 3
In Uship Federal Circuit Finds Prosecution History Disclaimer in Arguments Against Restriction Requirement 23 May 2013 PharmaPatents In Uship Intellectual Properties, LLC v. United States, the Federal Circuit upheld the claim construction applied by the Court of Federal Claims when it held that...
USPTO Launches New After Final Consideration Pilot Program to Reduce Requests for Continued Examination (RCEs) 20 May 2013 PharmaPatents In a Federal Register Notice published on May 17, 2013, the USPTO announced After Final Consideration Pilot Program 2.0 (AFCP 2.0) as part of its ongoing efforts...
Supreme Court Finds for Monsanto in Seed Harvesting Case 16 May 2013 PharmaPatents In Bowman v. Monsanto Co., the Supreme Court held that the doctrine of patent exhaustion does not give a farmer who has bought patented seeds the right to “reproduce”...
Federal Circuit Issues Fractured Affirmance in CLS Bank v. Alice Corporation 13 May 2013 PharmaPatents In a fractured en banc decision, the Federal Circuit affirmed the district court’s holding that the claims at issue in CLS Bank v. Alice Corporation are invalid...
USPTO Reshuffles the RCE Deck 09 May 2013 PharmaPatents The USPTO still is considering information gathered during its RCE Outreach program, but it has made some internal changes that should lead to more prompt examination...
Federal Circuit Upholds One Claim Covering Combigan 07 May 2013 PharmaPatents In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit reversed the district court in part, finding that Allergan’s composition claims and most of its method claims...
Federal Circuit Holds That Patent Indefiniteness Requires Insoluble Ambiguousness 02 May 2013 PharmaPatents In Biosig Instruments, Inc. v. Nautilus Inc., the Federal Circuit reversed the district court’s finding that the claims at issue were invalid as indefinite, because...
Dispelling the Myriad Gene Patent Harmonization Myth 30 April 2013 PharmaPatents In the wake of the Supreme Court oral arguments in the Myriad “gene patent” case, most commentators are predicting that the Court will uphold the patent-eligibility...
Federal Circuit Finds Yaz Patent Obvious 25 April 2013 PharmaPatents In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer’s patent covering...
Challenging the Enabling Quality of Prior Art 18 April 2013 PharmaPatents In In re Morsa, the Federal Circuit reversed an anticipation rejection where the applicant had challenged the enabling quality of the cited prior art reference,...